Can-Fite BioPharma Ltd. (TLV:CANF)

Market Cap	16.40M -72.6%
Revenue (ttm)	1.89M -16.0%
Net Income	-29.65M
EPS	-29.93
Shares Out	2.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,537
Average Volume	27,072
Open	595.20
Previous Close	618.30
Day's Range	595.20 - 645.10
52-Week Range	560.00 - 8,100.00
Beta	-0.41
RSI	43.32
Earnings Date	Mar 27, 2026

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 5
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: CANF

Financial Performance

In 2024, Can-Fite BioPharma's revenue was $674,000, a decrease of -9.29% compared to the previous year's $743,000. Losses were -$7.88 million, 3.22% more than in 2023.

Financial numbers in USD